Executives at Adaptive Biotechnologies Corp have recently sold significant portions of their holdings.

Michelle Renee Griffin, a Director at the company, sold 48,044 shares of common stock on March 3, 2026. The shares were sold at a weighted average price of $15.30 per share, totaling $735,073. After the transaction, Griffin continues to hold 15,394 shares of the company.

Meanwhile, Julie Rubinstein, President and COO, sold 92,823 shares over three days from March 3 to March 5, 2026. The sales occurred at weighted average prices ranging from $15.49 to $16.60, amounting to a total of $1,493,427. Rubinstein now directly owns 575,235 shares of Adaptive Biotechnologies.

These insider transactions were reported in SEC Form 4 filings, highlighting the executives’ recent stock activity.